rt2 mir first strand kit (Qiagen)
Qiagen is a verified supplier 
Qiagen manufactures this product 
99
Structured Review
Qiagen
rt2 mir first strand kit
Rt2 Mir First Strand Kit, supplied by Qiagen, used in various techniques. Bioz Stars score: 99/100, based on 3400 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rt2+mir+first+strand+kit/miRNeasy+Micro+Kit/pm40682948-98-21-26
Average 99 stars, based on 3400 article reviews
Rt2 Mir First Strand Kit, supplied by Qiagen, used in various techniques. Bioz Stars score: 99/100, based on 3400 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rt2+mir+first+strand+kit/miRNeasy+Micro+Kit/pm40682948-98-21-26
Average 99 stars, based on 3400 article reviews
rt2 mir first strand kit - by Bioz Stars,
2026-10
99/100 stars
Images
Related Articles
Amplification:Article Title: miR-145 micelles mitigate atherosclerosis by modulating vascular smooth muscle cell phenotype. Article Snippet: .. The aortic root region was harvested, weighed, and lysed with Trizol (Invitrogen, Carlsbad, CA). miR was extracted from aortas of ApoE− /- mice by miRNeasy Mini Kit (Qiagen, Hilden, Germany) and linearly amplified with Article Title: Genetically engineering cells to produce therapeutically boosted extracellular vesicles for cardiovascular calcification. Article Snippet: Calcification associated with atherosclerosis is a major driver of morbidity globally.. Despite the correlation of calcification with plaque rupture and sudden death, there are no clinically approved therapies that treat vascular calcification.. Notably, vascular smooth muscle cells (VSMCs) represent a promising target to inhibit vascular calcification, as VSMCs are the primary source of calcification deposition in the vasculature. Isolation:Article Title: Developing Therapeutically Enhanced Extracellular Vesicles for Atherosclerosis Therapy. Article Snippet: Atherosclerosis is a chronic condition and the leading cause of death worldwide.. While statin therapy is the clinical standard, many patients still experience acute cardiovascular events.. To develop better therapies, the group previously delivered microRNA-145 (miR-145) via micellar nanoparticles to vascular smooth muscle cells (VSMCs) to inhibit atherosclerosis. Synthesized:Article Title: Developing Therapeutically Enhanced Extracellular Vesicles for Atherosclerosis Therapy. Article Snippet: Atherosclerosis is a chronic condition and the leading cause of death worldwide.. While statin therapy is the clinical standard, many patients still experience acute cardiovascular events.. To develop better therapies, the group previously delivered microRNA-145 (miR-145) via micellar nanoparticles to vascular smooth muscle cells (VSMCs) to inhibit atherosclerosis. Real-time Polymerase Chain Reaction:Article Title: Developing Therapeutically Enhanced Extracellular Vesicles for Atherosclerosis Therapy. Article Snippet: Atherosclerosis is a chronic condition and the leading cause of death worldwide.. While statin therapy is the clinical standard, many patients still experience acute cardiovascular events.. To develop better therapies, the group previously delivered microRNA-145 (miR-145) via micellar nanoparticles to vascular smooth muscle cells (VSMCs) to inhibit atherosclerosis. SYBR Green Assay:Article Title: Developing Therapeutically Enhanced Extracellular Vesicles for Atherosclerosis Therapy. Article Snippet: Atherosclerosis is a chronic condition and the leading cause of death worldwide.. While statin therapy is the clinical standard, many patients still experience acute cardiovascular events.. To develop better therapies, the group previously delivered microRNA-145 (miR-145) via micellar nanoparticles to vascular smooth muscle cells (VSMCs) to inhibit atherosclerosis. |